Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO-DALBA trial of dalbavancin plus rifampicin for staphylococcal prosthetic joint infection
2024-518183-12-00Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Mar 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalbavancin and rifampicin in periprosthetic joint infection (PJI) and Staphylococcal periprosthetic joint infection (SPJI), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Treatment success at 12 months. Started Mar 2022; status: completed.
02
Drugs
dalbavancinrifampicin
03
Conditions
periprosthetic joint infection (PJI)Staphylococcal periprosthetic joint infection (SPJI)
Beyond the preview
Go deeper on 2024-518183-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518183-12-00.